6.00
6.00 (0%)
As of Feb 14, 2025
Optinose, Inc. [OPTN]
Source:
Company Overview
Optinose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
| Country | United States |
| Headquarters | yardley, pennsylvania |
| Phone Number | (267) 364-3500 |
| Industry | manufacturing |
| CEO | Ramy Mahmoud |
| Website | www.optinose.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $78.2 |
| Operating Profit | $-16.3 |
| Net Income | $-21.5 |
| Net Cash | $10.8 |
Profit Ratios
| Gross Margin | $71 |
| Operating Margin | -20.9 |
| Profit as % of Revenues | -329.6% |
| Profit as % of Assets | -18.2% |
| Profit as % of Stockholder Equity | 53.4% |
Management Effectiveness
| Return on Equity | 53.4% |
| Return on Assets | -16.7% |
| Turnover Ratio | 66.2% |
| EBITA | $-16.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $128.8 |
| Total Liabilities | $169.1 |
| Operating Cash Flow | $-44.7 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $55.6 |
